112 related articles for article (PubMed ID: 38184863)
21. Identifying a Hypoxia-Related Long Non-Coding RNAs Signature to Improve the Prediction of Prognosis and Immunotherapy Response in Hepatocellular Carcinoma.
Tang P; Qu W; Wang T; Liu M; Wu D; Tan L; Zhou H
Front Genet; 2021; 12():785185. PubMed ID: 34917132
[No Abstract] [Full Text] [Related]
22. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
23. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
[TBL] [Abstract][Full Text] [Related]
24. Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma.
Feng J; Wei X; Liu Y; Zhang Y; Li G; Xu Y; Zhou P; Zhang J; Han X; Zhang C; Zhang Y; Wang G
Aging (Albany NY); 2023 Nov; 15(22):13010-13040. PubMed ID: 37980167
[TBL] [Abstract][Full Text] [Related]
25. Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.
Feng NN; Du XY; Zhang YS; Jiao ZK; Wu XH; Yang BM
Front Endocrinol (Lausanne); 2022; 13():1061091. PubMed ID: 36714595
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Signature and Tumor Immune Landscape of N7-Methylguanosine-Related lncRNAs in Hepatocellular Carcinoma.
Wei W; Liu C; Wang M; Jiang W; Wang C; Zhang S
Front Genet; 2022; 13():906496. PubMed ID: 35938009
[TBL] [Abstract][Full Text] [Related]
27. Multi-omic profiling reveals potential biomarkers of hepatocellular carcinoma prognosis and therapy response among mitochondria-associated cell death genes in the context of 3P medicine.
Hu D; Shen X; Gao P; Mao T; Chen Y; Li X; Shen W; Zhuang Y; Ding J
EPMA J; 2024 Jun; 15(2):321-343. PubMed ID: 38841626
[TBL] [Abstract][Full Text] [Related]
28. A Prognostic Model Based on NSUN3 Was Established to Evaluate the Prognosis and Response to Immunotherapy in Liver Hepatocellular Carcinoma.
Zhu J; Kuang J; Yang Y; Zhang L; Leng B; She R; Zou L
Mediators Inflamm; 2023; 2023():6645476. PubMed ID: 37114236
[TBL] [Abstract][Full Text] [Related]
29. Landscape of associations between long non-coding RNAs and infiltrating immune cells in liver hepatocellular carcinoma.
Li L; Song X; Lv Y; Jiang Q; Fan C; Huang D
J Cell Mol Med; 2020 Oct; 24(19):11243-11253. PubMed ID: 32910548
[TBL] [Abstract][Full Text] [Related]
30. The Prognostic Significance of
Li Z; Cui Y; Duan Q; Zhang J; Shao D; Cao X; Gao Y; Wang S; Li J; Jones OD; Lei X; Wang L; Zhou X; Xu M; Ma J; Liu Y; Xu X
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361587
[TBL] [Abstract][Full Text] [Related]
31. Construction and Validation of Two Hepatocellular Carcinoma-Progression Prognostic Scores Based on Gene Set Variation Analysis.
He Q; Fan B; Du P; Jin Y
Front Cell Dev Biol; 2022; 10():806989. PubMed ID: 35356272
[No Abstract] [Full Text] [Related]
32. Machine learning-based prognostic modeling of lysosome-related genes for predicting prognosis and immune status of patients with hepatocellular carcinoma.
Li W; Wang Q; Lu J; Zhao B; Geng Y; Wu X; Chen X
Front Immunol; 2023; 14():1169256. PubMed ID: 37275878
[TBL] [Abstract][Full Text] [Related]
33. Combining a machine-learning derived 4-lncRNA signature with AFP and TNM stages in predicting early recurrence of hepatocellular carcinoma.
Fu Y; Si A; Wei X; Lin X; Ma Y; Qiu H; Guo Z; Pan Y; Zhang Y; Kong X; Li S; Shi Y; Wu H
BMC Genomics; 2023 Feb; 24(1):89. PubMed ID: 36849926
[TBL] [Abstract][Full Text] [Related]
34. The integration of machine learning and multi-omics analysis provides a powerful approach to screen aging-related genes and predict prognosis and immunotherapy efficacy in hepatocellular carcinoma.
Shen J; Gao H; Li B; Huang Y; Shi Y
Aging (Albany NY); 2023 Jul; 15(14):6848-6864. PubMed ID: 37517087
[TBL] [Abstract][Full Text] [Related]
35. Anoikis-related signature in liver hepatocellular carcinoma defines the YBX1/SPP1 axis by machine learning strategies and valid experiments.
Ma Y; She X; Zhao J; Liu S; Li C; Wang Q
J Gene Med; 2023 Oct; 25(10):e3516. PubMed ID: 37118998
[TBL] [Abstract][Full Text] [Related]
36. FANCI is Associated with Poor Prognosis and Immune Infiltration in Liver Hepatocellular Carcinoma.
Hou Y; Li J; Yu A; Deng K; Chen J; Wang Z; Huang L; Ma S; Dai X
Int J Med Sci; 2023; 20(7):918-932. PubMed ID: 37324186
[No Abstract] [Full Text] [Related]
37. The Prognostic and Therapeutic Role of Histone Acetylation Modification in LIHC Development and Progression.
Gao J; Han S; Gu J; Wu C; Mu X
Medicina (Kaunas); 2023 Sep; 59(9):. PubMed ID: 37763801
[No Abstract] [Full Text] [Related]
38. Investigation of Hippo pathway-related prognostic lncRNAs and molecular subtypes in liver hepatocellular carcinoma.
Su Q; Hua F; Xiao W; Liu B; Wang D; Qin X
Sci Rep; 2023 Mar; 13(1):4521. PubMed ID: 36941336
[TBL] [Abstract][Full Text] [Related]
39. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
[TBL] [Abstract][Full Text] [Related]
40. Identification of anoikis related subtypes and construction of prognostic model in hepatocellular carcinoma.
Fang W; Chen Z
Cell Mol Biol (Noisy-le-grand); 2023 Sep; 69(9):219-228. PubMed ID: 37807308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
